April 21, 2025

Lupus Clusters Show Distinct Disease Patterns

Cluster 2 patients exhibited ‘a more severe form of the disease, marked with frequent serositis and haematological manifestations, renal and neurological involvement,’ and had poorer outcomes over time.

Conexiant

April 18, 2025

FDA Approves New Spontaneous Urticaria Therapy

The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.

Conexiant

April 18, 2025

Vaccination May Lower RA Risk

Researchers found no increased risk of rheumatoid arthritis following vaccination. In fact, they observed short-term protective effects against RA.

Conexiant

April 17, 2025

Climate Identified as Key Virus Driver

Researchers found Oropouche virus to be underreported during a large-scale study across Latin America, with climate emerging as the primary driver of transmission risk.

Conexiant

April 16, 2025

Is Primary Care Becoming Pay-to-Play?

“It’s a way to practice self-preservation in this field that is punishing patients and doctors alike” — one internist explains why some rural physicians are opting for concierge care despite the access trade-offs.

KFF Health News

April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant

April 14, 2025

Inebilizumab Effective for Myasthenia Gravis

CD19+ B-cell-depleting therapy shows significant improvement in function and disease severity in phase III trial of autoimmune neuromuscular disorder.

Conexiant

April 11, 2025

New Meta-Analysis Updates Vitamin D Evidence

This meta-analysis of 46 randomized trials found no statistically significant effect of vitamin D supplementation on acute respiratory infection prevention overall or across subgroups.

Conexiant

April 11, 2025

New Self-Injection Option for gMG, CIDP

A prefilled syringe version of VYVGART Hytrulo, which enables adult patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy to self-administer treatment in as little as 20 to 30 seconds, has been approved by the FDA.

Conexiant